Immunological differences between squamous cell cancer patients treated with and without biological response modifier (OK-432): evaluation at a period of more than one year after the last treatment.
The cellular immunity of peripheral blood was analyzed to evaluate the efficacy of OK-432 between 3 groups of patients with oromaxillary squamous cell cancer, which were composed of 14 patients in the pretreatment stage, 8 patients who were free from cancer more than one year after the last cancer therapy and had been continuously treated with OK-432, and 14 patients who had undertaken cancer therapy without OK-432 and were also free from cancer for at least one year. As parameters of cellular immunity, leucocyte counts, percent composition of T-cells, percent compositions of T-lymphocyte subsets (OKIal+, OKT3+, OKT4+, and OKT8+) and the ratio of OKT4+ and OKT8+, PPD skin test, and lymphocytic blastogenesis induced by PHA and Con-A, were examined. The results showed no significant difference between the patients treated with and without OK-432. Nor was there any significant difference between the pretreatment group and the posttreatment groups with and without OK-432 treatments in any of the examined immunologic parameters.
Yoshimura
Y
Y
Oka
M
M
Harada
T
T
Inou
Y
Y
Saito
H
H
Odagawa
T
T
Matsumoto
K
K
D000328:Adult; D000368:Aged; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007167:Immunotherapy; D007573:Jaw Neoplasms / Q000276:immunology / Q000628:therapy*; D007958:Leukocyte Count / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000276:immunology / Q000628:therapy*; D010844:Picibanil / Q000627:therapeutic use*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects
D010844:Picibanil